Rivaroxaban for atrial fibrillation patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have atrial fibrillation confirmed by an ECG
- You have a CHA2DS2-VASc score of 1 or more (for men) or 2 or more (for women), meaning you have at least one stroke risk factor
- Your kidney function (creatinine clearance) is 50 ml/min or higher
- You do not have a history of certain bleeding conditions, liver disease, or other high-risk issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a 'pill-in-the-pocket' approach for blood thinners after a catheter ablation for atrial fibrillation. Instead of taking a daily blood thinner, you may only take it when needed, which could reduce the risk of bleeding while still preventing strokes.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
This study compares two common blood thinners, apixaban and rivaroxaban, in veterans with atrial fibrillation or flutter to see which one is safer and works better. If you are already taking one of these medicines, you may be able to join.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This study looks at whether a lower-dose blood thinner works as well as the usual recommended anti-clot treatment after a procedure that closes off the heart’s left atrial appendage. It may help reduce bleeding risk while still preventing dangerous blood clots.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.